Google DeepMind 's drug discovery arm, Isomorphic Labs, is almost ready to begin human trials of its AI-designed drugs. In an interview with Fortune, Colin Murdoch, President of Isomorphic Labs ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...

After years of development, Murdoch says human clinical trials for Isomorphic’s AI-designed drugs are finally within reach.

According to Colin Murdoch, president of Isomorphic Labs and DeepMind’s chief business officer, the company is close to achieving a major milestone by putting AI-designed drugs into human trials.

Colin Murdoch, the company’s president and also Google DeepMind’s chief business officer, confirmed to Fortune that trials for AI-designed drugs could begin in the near future.

Colin Murdoch, president of Isomorphic Labs and Chief Business Officer at DeepMind, reportedly said the company is “getting very close” to launching its first clinical trial.

Colin Murdoch, Isomorphic Labs president and Google DeepMind’s chief business officer, believes using cutting-edge AI in pharma could not only accelerate drug development but also cut costs ...

In a recent interview with Fortune, Isomorphic Labs President Colin Murdoch said the company is “very close” to starting clinical trials.